Sanofi-Aventis said on Thursday its anti-obesity drug Acomplia would be reimbursed by French social security when prescribed to certain obese diabetics, but only after other treatment proved insufficient.
The French health authority's Transparency Committee agreed last month to recommend that Acomplia be reimbursed only when it is prescribed to obese patients with type 2 diabetes and with certain blood sugar levels.
Under conditions published on Thursday, doctors must first try out other targeted therapies and must place the patient on a special diet and physical exercise, Sanofi said.
The drug will go on sale at 71.63 euros ($95) for 28 days' supply and patients will get a 35% reimbursment.
More at Reuters
No comments:
Post a Comment